US FDA Approved BeiGene’s BRUKINSA to Treat Chronic Lymphocytic Leukemia

The global biotechnology company BeiGene announced that the Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with CLL or SLL has received approval from the U.S. Food and Drug Administration (FDA). Mehrdad Mobasher, Chief Medical Officer, Hematology at BeiGene, said that they believe BRUKINSA is well-positioned to become the BTKi […]

Continue Reading